Inhibition of EGFR-STAT3 signaling with erlotinib prevents carcinogenesis in a chemically-induced mouse model of oral squamous cell carcinoma

Cancer Prevention Research

Volumn 4, Issue 2, 2011, Pages 230-237

  Leeman Neill, Rebecca J ^a   Seethala, Raja R ^a   Singh, Shivendra V ^a   Freilino, Maria L ^b   Bednash, Joseph S ^b   Thomas, Sufi M ^b   Panahandeh, Mary C ^b   Gooding, William E ^c   Joyce, Sonali C ^b   Lingen, Mark W ^e   Neill, Daniel B ^d   Grandis, Jennifer R ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d CARNEGIE MELLON UNIVERSITY   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GUGGULSTERONE; STAT3 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA;

4-NITROQUINOLINE-1-OXIDE; ANIMAL FEED; ANIMALS; CARCINOGENS; CARCINOMA, SQUAMOUS CELL; COMMIPHORA; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOENZYME TECHNIQUES; MICE; MICE, INBRED CBA; MOUTH NEOPLASMS; PLANT EXTRACTS; PLANT GUMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 79551711693     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-10-0249     Document Type: Article

References (36)

1. Sturgis EM. A review of social and behavioral efforts at oral cancer preventions in India. Head Neck 2004;26:937-44. (Pubitemid 39488120)
2. Day GL, Blot WJ. Second primary tumors in patients with oral cancer. Cancer 1992;70:14-9.
3. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium: clinical implications of multicentric origin. Cancer 1953;6:963-8.
4. Wolbach SB, Howe PR. Nutrition classics. The Journal of Experimental Medicine 42:753-77, 1925.
5. Tissue changes following deprivation of fat-soluble A vitamin. S. Burt Wolbach and Percy R. Howe. Nutr Rev 1978;36:16-9.
6. Hong WK, Endicott J, Itri LM, Doos W, Batsakis JG, Bell R, et al. 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986;315:1501-5. (Pubitemid 17052146)
7. Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, Byers RM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990;323:795-801. (Pubitemid 20303877)
8. Khuri FR, Lee JJ, Lippman SM, Kim ES, Cooper JS, Benner SE, et al. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst 2006;98:441-50.
9. Lippman SM, Lee JJ, Karp DD, Vokes EE, Benner SE, Goodman GE, et al. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst 2001;93:605-18.
10. Kim JW, Amin AR, Shin DM. Chemoprevention of head and neck cancer with green tea polyphenols. Cancer Prev Res 2010;3:900-9.
11. Pisters KM, Newman RA, Coldman B, Shin DM, Khuri FR, Hong WK, et al. Phase I trial of oral green tea extract in adult patients with solid tumors. J Clin Oncol 2001;19:1830-8. (Pubitemid 32230886)
12. Schwartz JL, Baker V, Larios E, Chung FL. Molecular and cellular effects of green tea on oral cells of smokers: a pilot study. Mol Nutr Food Res 2005;49:43-51.
13. Armstrong WB, Kennedy AR, Wan XS, Taylor TH, Nguyen QA, Jensen J, et al. Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase IIa chemoprevention trial. Clin Cancer Res 2000;6:4684-91. (Pubitemid 32110405)
14. Khuri FR, Shin DM. Head and neck cancer chemoprevention gets a shot in the arm. J Clin Oncol 2008;26:345-7. (Pubitemid 351171680)
15. Czerninski R, Amornphimoltham P, Patel V, Molinolo AA, Gutkind JS. Targeting mammalian target of rapamycin by rapamycin prevents tumor progression in an oral-specific chemical carcinogenesis model. Cancer Prev Res 2009;2:27-36.
16. Hasina R, Martin LE, Kasza K, Jones CL, Jalil A, Lingen MW. ABT-510 is an effective chemopreventive agent in the mouse 4-nitroquinoline 1-oxide model of oral carcinogenesis. Cancer Prev Res 2009;2:385-93.
17. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993;53:3579-84. (Pubitemid 23229640)
18. Taoudi Benchekroun M, Saintigny P, Thomas SM, El-Naggar AK, Papadimitrakopoulou V, Ren H, et al. Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. Cancer Prev Res 2010;3:800-9.
19. Ohashi K, Takigawa N, Osawa M, Ichihara E, Takeda H, Kubo T, et al. Chemopreventive effects of gefitinib on nonsmoking-related lung tumorigenesis in activating epidermal growth factor receptor transgenic mice. Cancer Res 2009;69:7088-95.
20. Saba N, Muller S, Chen AY, Grist W, Gibson K, Nannapaneni S, Yang CS, Khuri FR, Chen ZG, Shin DM. Chemoprevention with erlotinib and celecoxib in advanced premalignant lesions of the head and neck: results of a phase I study. J Clin Oncol 2010 ASCO Annu Meeting Proc 2010;28:5535.
21. Anderson M.D. Cancer Center. Erlotinib prevention of oral cancer. In: ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US)2000-[cited 2011 Sept 11] Available from: http://wwwclinicaltrialsgov/show/ NCT00402779NLM identifier: NCT00402779.
22. Sidney Kimmel Cancer Center. Cetuximab in Treating Patients With Precancerous Lesions of the Upper Aerodigestive Tract. In: Clinical-Trialsgov [Internet]Bethesda (MD): National Library of Medicine (US) 2000-[cited 2011 Sept 11] Available from: http://wwwclinicaltrialsgov/show/NCT00524017NLM identifier: NCT00524017.
23. Leeman RJ, Lui VW, Grandis JR. STAT3 as a therapeutic target in head and neck cancer. Expert Opin Biol Ther 2006;6:231-41. (Pubitemid 43344743)
24. Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melhem MF, Endo S, et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci USA 2000;97:4227-32. (Pubitemid 30226115)
25. Urizar NL, Moore DD. GUGULIPID: a natural cholesterol-lowering agent. Annu Rev Nutr 2003;23:303-13. (Pubitemid 37059726)
26. Shishodia S, Harikumar KB, Dass S, Ramawat KG, Aggarwal BB. The guggul for chronic diseases: ancient medicine, modern targets. Anticancer Res 2008;28:3647-64.
27. Leeman-Neill RJ, Wheeler SE, Singh SV, Thomas SM, Seethala RR, Neill DB, et al. Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3. Carcinogenesis 2009;30:1848-56.
28. Agarwal RC, Singh SP, Saran RK, Das SK, Sinha N, Asthana OP, et al. Clinical trial of gugulipid-a new hypolipidemic agent of plant origin in primary hyperlipidemia. Indian J Med Res 1986;84:626-34.
29. Hawkins BL, Heniford BW, Ackermann DM, Leonberger M, Martinez SA, Hendler FJ. 4NQO carcinogenesis: a mouse model of oral cavity squamous cell carcinoma. Head Neck 1994;16:424-32. (Pubitemid 24262590)
30. Tang XH, Knudsen B, Bemis D, Tickoo S, Gudas LJ. Oral cavity and esophageal carcinogenesis modeled in carcinogen-treated mice. Clin Cancer Res 2004;10:301-13. (Pubitemid 38114193)
31. Thomas SM, Grandis JR. Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treat Rev 2004;30:255-68. (Pubitemid 38477271)
32. Cornick CL, Strongitharm BH, Sassano G, Rawlins C, Mayes AE, Joseph AN, et al. Identification of a novel agonist of peroxisome proliferator-activated receptors alpha and gamma that may contribute to the anti-diabetic activity of guggulipid in Lep(ob)/Lep(ob) mice. J Nutr Biochem 2009;20:806-15.
33. Cui J, Huang L, Zhao A, Lew JL, Yu J, Sahoo S, et al. Guggulsterone is a farnesoid X receptor antagonist in coactivator association assays but acts to enhance transcription of bile salt export pump. J Biol Chem 2003;278:10214-20. (Pubitemid 36800282)
34. Grandis JR, Drenning SD, Chakraborty A, Zhou MY, Zeng Q, Pitt AS, et al. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth in vitro. J Clin Invest 1998;102:1385-92. (Pubitemid 28467567)
35. Li T, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol 2009;4:107-19.
36. Brobst DE, Ding X, Creech KL, Goodwin B, Kelley B, Staudinger JL. Guggulsterone activates multiple nuclear receptors and induces CYP3A gene expression through the pregnane X receptor. J Pharmacol Exp Ther 2004;310:528-35. (Pubitemid 38988896)